Modern Prostate Cancer Screening Pipeline
Attia's modern, multi-step approach to prostate cancer screening that replaces the old PSA→ultrasound→transrectal biopsy→treat algorithm. Uses longitudinal PSA, MRI-derived density, contrast-free MRI when possible, transperineal biopsy if needed, and active surveillance with adjunctive biomarkers for low-grade disease.
Assembled by Cited from Peter Attia's recorded recommendations across multiple sources. It is not an ordered program and was not created or endorsed by them — it's our grouping of what they've said on the record.
Components
10-
In a protocol
Attia strongly recommends regular PSA blood testing for men as a cheap, effective screening tool to catch prostate cancer early.
“regular PSA testing is so important if one of our objectives in life would be to eliminate prostate cancer mortality
TP▶ 2:00DosageRoutine blood draw; interpret longitudinally over time, not as single valueCaveatsSingle values are noisy; daily fluctuation up to 15%, ejaculation can spike 40%Certaintyexplicitstrong endorsementRoutine PSA blood test as the entry point -
In a protocol
Track rate of change in PSA over time (18-month windows) rather than relying on single snapshot values to detect concerning trends.
“PSA is most value as a longitudinal trend, not a single snapshot
TP▶ 15:00DosageIf baseline PSA <4: flag rise >0.35 ng/mL/year over 18 months. If baseline >4: flag rise >0.75 ng/mL/year.Certaintyexplicitstrong endorsementInterpret PSA longitudinally via velocity, not single snapshot -
In a protocol
Use MRI as next step after concerning PSA velocity, before biopsy, to identify suspicious lesions and calculate PSA density.
“the next step would now be an MRI, which serves as a much higher resolution test
TP▶ 19:00DosageMultiparametric (T2, diffusion, dynamic contrast-enhanced) or biparametric (no contrast)CaveatsMultiparametric requires gadolinium contrast and longer scan timeCertaintyexplicitstrong endorsementMRI as next step when velocity flags concern; multiparametric is gold standard -
In a protocol
Contrast-free MRI variant shown non-inferior to multiparametric MRI in PRIME trial; faster, cheaper, more accessible.
“the bi-parametric MRI identified clinically significant cancer in 143 out of 490 men
TP▶ 22:00Dosage15-20 minutes, no gadolinium contrast requiredCertaintyexplicitrecommendationContrast-free biparametric MRI is non-inferior per PRIME trial; faster/cheaper alternative to multiparametric -
In a protocol
Calculate PSA concentration divided by prostate volume from imaging to detect disproportionate PSA leakage suggestive of malignancy.
“PSA density, which is simply the PSA concentration in the blood divided by the volume of the prostate
TP▶ 19:30DosagePSA divided by prostate volume from MRI or ultrasoundCertaintyexplicitrecommendationPSA density calculated from MRI volume adds discriminating power -
In a protocol
Prefer transperineal over transrectal biopsy approach due to near-zero infection rate and better access to anterior/apical prostate.
“not a single patient who underwent the transperineal biopsy in that study developed an infection
TP▶ 24:00DosageEntry through perineum (skin between anus and scrotum), no prophylactic antibiotics neededCaveatsOnly ~37% of US urologists currently perform thisCertaintyexplicitstrong endorsementTransperineal biopsy if biopsy warranted -
In a protocol
Older transrectal biopsy approach carries 5-7% infection risk and misses anterior/apical tumors; should be replaced where possible.
“infection rates from these biopsies ran between 5% and 7%
TP▶ 8:30CaveatsStill widely practicedCertaintyexplicitmild cautionOlder transrectal approach explicitly cautioned against in favor of transperineal -
In a protocol
For low-grade (Gleason 3+3) prostate cancers, monitor with serial testing rather than immediate treatment to avoid overtreatment harms.
“active surveillance is basically something we're doing to ensure that treatment will be timely once it is required, but no sooner
TP▶ 28:30DosageMonitor with PSA, MRI, and additional markers like PHI or 4K scoreCertaintyexplicitstrong endorsementActive surveillance for low-grade (Gleason 3+3 / grade group 1-2) findings -
In a protocol
Use Prostate Health Index blood marker as additional risk stratification tool in low-grade prostate cancer surveillance.
“other blood markers like tests called the PHI or the 4K score
TP▶ 28:00CertaintyexplicitrecommendationPHI biomarker as adjunct during active surveillance
How this protocol has evolved
Attia explicitly contrasts the modern pipeline (PSA velocity → MRI + PSA density → transperineal biopsy if needed → active surveillance for low-grade) with the obsolete 1990s/2000s pipeline (single PSA → ultrasound → transrectal biopsy → treat all). PRIME trial (2025) enables biparametric MRI as a more accessible substitute for multiparametric MRI.